Implanet to Participate at the Roth Capital 28th Conference in California

Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announced today that management will participate and present at the 28th Annual ROTH Conference in Laguna Niguel, CA, to be held from Monday, March 14 to Wednesday, March 16, 2016.

Ludovic Lastennet, CEO of Implanet will present on Wednesday, March 16 at 7:00 AM and will provide an overview of the Company’s operations. He will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

ROTH Capital 28th Annual Conference is one of the largest of its kind in the US. Following the success of previous years’ events, the ROTH Conference, with over 500 participating companies and over 3,000 attendees, will feature presentations from hundreds of public and private companies in a variety of sectors.

Next financial press release: 2015 annual results, on March 30, 2016 (after market).

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2015 sales of €6.7 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160309005959/en/